Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands

被引:24
|
作者
Janssen-Heijnen, Maryska L. [1 ,2 ]
van Steenbergen, Liza N. [2 ]
Steyerberg, Ewout [3 ]
Visser, Otto [4 ]
De Ruysscher, Dirk K. [5 ]
Groen, Harry J. [6 ]
机构
[1] VieCuri Med Ctr, Dept Clin Epidemiol, NL-5900 BX Venlo, Netherlands
[2] Eindhoven Canc Registry, Comprehens Canc Ctr S, Eindhoven, Netherlands
[3] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands
[4] Comprehens Canc Ctr Netherlands, Dept Registrat & Res, Amsterdam, Netherlands
[5] Maastricht Univ Med Ctr, Dept Radiat Oncol, Maastro Clin, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 AV Groningen, Netherlands
关键词
Conditional survival; Non-small cell lung cancer; Long-term survivors; Excess mortality; UP-TO-DATE; CONDITIONAL SURVIVAL; PATIENT SURVIVAL; PERIOD ANALYSIS; ALTERNATIVE APPROACH; CARCINOMA; RATES; EPIDEMIOLOGY; PROGNOSIS; LOBECTOMY;
D O I
10.1097/JTO.0b013e318241f80b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Most patients diagnosed with non-small cell lung cancer (NSCLC) die within the first few years after diagnosis. However, only little is known about those who have survived these first years. We aimed to study conditional 5-year relative survival rates for NSCLC patients during long-term follow-up. Methods: All 12,148 patients aged 45 to 74 years diagnosed with stage I-III NSCLC between 1989 and 2008 in the Netherlands were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every additional year survived up to 15 years. Results: Conditional 5-year relative survival rapidly improved with every year survived up to 4 to 5 years after diagnosis. However, a significant excess mortality of 20 to 40% remained. Conditional 5-year relative survival for those aged 45 to 59 years did not exceed 80% for survivors with stage I or II disease and remained just more than 70% for those with stage III disease. For those aged 60 to 74 years, these proportions were 70%, 65%, and 60%, respectively. Conclusions: A significant excess mortality remains in lung cancer after years which may be explained by excess risk of death due to smoking-related comorbidity in these patients. Caregivers should use this information for planning optimal cancer surveillance and informing cancer survivors about their actual prognosis.
引用
收藏
页码:496 / 502
页数:7
相关论文
共 50 条
  • [21] Minimal excess mortality for long-term colon cancer survivors in the Netherlands 1989-2008
    van Steenbergen, L. N.
    Steur, M.
    Lemmens, V. E. P. P.
    Rutten, H. J. T.
    van Spronsen, D. J.
    Janssen-Heijnen, M. L. G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (03) : 585 - 592
  • [22] Quality of life of long-term survivors of non-small-cell lung cancer
    Sarna, L
    Padilla, G
    Holmes, C
    Tashkin, D
    Brecht, ML
    Evangelista, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) : 2920 - 2929
  • [23] Long-term outcomes of completion pneumonectomy for non-small cell lung cancer
    Sezen, Celal Bugra
    Kocaturk, Celalettin Ibrahim
    Bilen, Salih
    Kalafat, Cem Emrah
    Aker, Cemal
    Karapinar, Kemal
    [J]. ACTA CHIRURGICA BELGICA, 2019, 119 (05) : 303 - 308
  • [24] Continued excess mortality for long-term prostate cancer survivors
    Husson, O.
    Van Steenbergen, L. N.
    Koldewijn, E. L.
    Poortmans, P. M.
    Coebergh, J. W. W.
    Janssen-Heijnen, M. L. G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S687 - S687
  • [25] Secondary primary cancer in the long-term survivors with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
    Takigawa, N.
    Segawa, Y.
    Kiura, K.
    Tabata, M.
    Ueoka, H.
    Yonei, T.
    Shibayama, T.
    Takata, I.
    Matsuo, K.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 400S - 400S
  • [26] Social determinants as predictors of resection and long-term mortality in Black patients with non-small cell lung cancer
    Coaston, Troy N.
    Sakowitz, Sara
    Chervu, Nikhil L.
    Branche, Corynn
    Shuch, Brian M.
    Benharash, Peyman
    Revels, Sha'Shonda
    [J]. SURGERY, 2024, 175 (02) : 505 - 512
  • [27] Impact of third-line chemotherapy on long-term survivors of advanced non-small cell lung cancer (NSCLC)
    Kim, T
    Kim, S
    Park, S
    Paek, J
    Choi, I
    Kim, D
    Kim, T
    Heo, D
    Bang, Y
    Kim, N
    [J]. LUNG CANCER, 2005, 49 : S252 - S253
  • [28] Definitive Results of a Clinical and Molecular Multicentric Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer
    Moreno-Rubio, J.
    Ponce, S.
    Alvarez, R.
    Olmedo, M. E.
    Falagan, S.
    Mielgo Rubio, X.
    Navarro, F.
    Cruz, P.
    Cabezon-Gutierrez, L.
    Munoz Fernandez De Leglaria, M.
    Enguita, A. B.
    Cebollero, M.
    Benito, A.
    Alemany, I.
    Del Castillo, C.
    Ramirez De Molina, A.
    Casado, E.
    Ramos, R.
    Colmenarejo, G.
    Sereno, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S917
  • [29] Clinical and Pathological Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
    Sereno Moyano, Maria
    Alvarez, Rosa
    Eugenia Olmedo, Maria
    Puente, Javier
    Mielgo, Xabier
    Navarro, Fatima
    Zambrana, Francisco
    Moreno-Rubio, Juan
    Garcia, Sagrario
    Casado, Enrique
    Sanchez, Ana
    Ponce, Santiago
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S462 - S463
  • [30] Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
    Moyano, M. Sereno
    Falagan, S.
    Rubio, J. Moreno
    Alvarez Alvarez, R.
    Olmedo, M. E.
    Mielgo, X.
    Navarro, F.
    Ramos, R.
    Enguita, A. B.
    Benito, A.
    Cebollero, M.
    Alemany, I.
    Castillo, C.
    Casado, E.
    Ponce Aix, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S900 - S900